Key Insights
The European nuclear medicine market, valued at approximately €X billion in 2025, is poised for robust growth, exhibiting a compound annual growth rate (CAGR) of 10% from 2025 to 2033. This expansion is fueled by several key drivers. Firstly, the increasing prevalence of chronic diseases like cancer and cardiovascular conditions necessitates advanced diagnostic and therapeutic tools, significantly boosting demand for nuclear medicine procedures. Secondly, technological advancements in areas like SPECT and PET imaging, coupled with the development of targeted alpha and beta emitters, are enhancing diagnostic accuracy and therapeutic efficacy, further driving market growth. The growing adoption of minimally invasive procedures and the increasing focus on personalized medicine are also contributing factors. Finally, supportive government initiatives and increasing healthcare expenditure in major European countries like Germany, France, and the UK are creating a favourable environment for market expansion. Within the application segments, oncology consistently holds the largest share, owing to the widespread use of nuclear medicine in cancer diagnosis and treatment. However, cardiology and neurology segments are also experiencing significant growth due to the rising incidence of related diseases and the adoption of innovative nuclear medicine technologies.
Europe Nuclear Medicine Industry Market Size (In Billion)
Despite the promising outlook, the European nuclear medicine market faces certain challenges. High costs associated with equipment, radiopharmaceuticals, and specialized personnel can limit accessibility, particularly in regions with strained healthcare budgets. Furthermore, stringent regulatory approvals and safety concerns related to radiation exposure necessitate robust quality control and safety protocols, potentially impacting market growth. However, ongoing research and development efforts focused on improving safety profiles and reducing costs are anticipated to mitigate these restraints in the long term. Competitive landscape analysis indicates that major players like GE Healthcare, Siemens Healthineers, and Bracco Imaging are focusing on strategic collaborations, product innovation, and market expansion to maintain their leadership positions, fostering further industry growth and market consolidation. The market is segmented by diagnostic modalities (SPECT, PET), therapeutic approaches (alpha, beta emitters, brachytherapy), and applications (cardiology, oncology, neurology). The dominance of oncology is expected to continue, but growth in other segments, particularly cardiology and neurology, is also anticipated.
Europe Nuclear Medicine Industry Company Market Share
Europe Nuclear Medicine Industry Market Report: 2019-2033
This comprehensive report provides an in-depth analysis of the European nuclear medicine market, covering the period from 2019 to 2033. It offers invaluable insights for industry professionals, investors, and stakeholders seeking to understand the market dynamics, growth drivers, and future opportunities within this rapidly evolving sector. The report leverages extensive data analysis and expert insights to deliver actionable strategies for success.
Europe Nuclear Medicine Industry Market Structure & Innovation Trends
The European nuclear medicine market is characterized by a moderately concentrated landscape, with key players such as Nordion Inc, GE Healthcare, Bracco Imaging SpA, Advanced Accelerator Applications, Cardinal Health Inc, Merck KGaA (Sigma-Aldrich), Siemens Healthineers AG, Curium Pharma, and others holding significant market share. The exact market share for each company is xx% for 2025 but varies year on year. Innovation is driven by advancements in imaging technologies (PET/SPECT), radiopharmaceutical development, and targeted therapies. Regulatory frameworks, such as those established by the European Medicines Agency (EMA), significantly impact market access and product approvals. Substitutes, including advanced MRI and CT scanning technologies, pose some competitive pressure, although the unique capabilities of nuclear medicine often maintain its vital role in diagnosis and treatment. End-user demographics, particularly the aging population and rising prevalence of chronic diseases, contribute to market expansion. Significant M&A activities, with deal values exceeding €xx Million in recent years, indicate consolidation within the industry. Examples include [Insert specific M&A examples if available, otherwise state "Further detailed M&A activity is detailed in the full report"].
- Market Concentration: Moderately concentrated with key players holding significant market share.
- Innovation Drivers: Advancements in imaging technologies, radiopharmaceutical development, and targeted therapies.
- Regulatory Framework: EMA regulations significantly influence market access.
- Product Substitutes: Advanced MRI and CT scanning technologies represent some competitive pressure.
- End-User Demographics: Aging population and rising prevalence of chronic diseases drive demand.
- M&A Activity: Significant M&A activity, with deal values exceeding €xx Million.
Europe Nuclear Medicine Industry Market Dynamics & Trends
The European nuclear medicine market is projected to experience robust growth, with a CAGR of xx% during the forecast period (2025-2033). This growth is fueled by several key factors. Technological advancements, such as the introduction of total-body PET scanners, are enhancing diagnostic capabilities and expanding clinical applications. Rising prevalence of cancer, cardiovascular diseases, and neurological disorders are increasing demand for nuclear medicine procedures. Furthermore, favorable reimbursement policies in many European countries support market expansion. However, competitive pressures from substitute technologies and regulatory complexities continue to present challenges. Market penetration of new technologies, such as alpha and beta emitters in targeted radionuclide therapies, is increasing steadily although penetration levels in 2025 are expected to be at xx%.
Dominant Regions & Segments in Europe Nuclear Medicine Industry
Within Europe, Germany, France, and the UK are the leading markets for nuclear medicine due to factors such as advanced healthcare infrastructure, high disease prevalence, and strong research capabilities. The Oncology segment dominates the applications market, representing xx% of the market in 2025. Within diagnostics, PET is experiencing faster growth than SPECT due to its superior image resolution. In therapeutics, the beta-emitters segment leads due to established clinical applications and ongoing development of innovative radiopharmaceuticals.
Leading Regions: Germany, France, and the UK
- Key Drivers: Advanced healthcare infrastructure, high disease prevalence, strong research and development.
Dominant Segments:
- By Diagnostics: Positron Emission Tomography (PET) showing faster growth than Single Photon Emission Computed Tomography (SPECT)
- By Therapeutics: Beta-emitters leading due to established clinical applications.
- By Application: Oncology segment dominating overall application market share.
Europe Nuclear Medicine Industry Product Innovations
Recent innovations focus on improving image quality, enhancing treatment efficacy, and streamlining workflows. These include the development of new radiopharmaceuticals with improved targeting and reduced toxicity. Total body PET scanners represent a significant advancement, allowing for whole-body imaging and disease detection. Technological advancements are improving the accuracy and speed of diagnostics, improving therapeutic options.
Report Scope & Segmentation Analysis
This report segments the European nuclear medicine market by diagnostics (SPECT, PET), therapeutics (alpha emitters, beta emitters, brachytherapy), and applications (cardiology, neurology, oncology, other). Each segment’s market size, growth projections, and competitive dynamics are analyzed in detail in the report. For instance, the PET segment is expected to exhibit a xx% CAGR between 2025 and 2033. Similarly detailed insights are provided for other segments.
Key Drivers of Europe Nuclear Medicine Industry Growth
The growth of the European nuclear medicine industry is primarily driven by technological advancements improving diagnostic and therapeutic capabilities, the rising prevalence of chronic diseases requiring advanced medical imaging and therapy, and supportive regulatory frameworks. Further, increased healthcare spending and investments in healthcare infrastructure across Europe provide momentum.
Challenges in the Europe Nuclear Medicine Industry Sector
Challenges include regulatory hurdles related to radiopharmaceutical approvals, supply chain complexities affecting the availability of radioisotopes, and intense competition from alternative imaging and treatment modalities. The cost of equipment and procedures is also a factor.
Emerging Opportunities in Europe Nuclear Medicine Industry
Emerging opportunities include the development of theranostics (combining diagnostics and therapeutics), personalized medicine approaches using nuclear medicine techniques, and the expansion of applications into new therapeutic areas. The utilization of AI and Machine Learning to analyze PET and SPECT data is also gaining considerable traction.
Leading Players in the Europe Nuclear Medicine Industry Market
- Nordion Inc
- GE Healthcare
- Bracco Imaging SpA
- Advanced Accelerator Applications
- Cardinal Health Inc
- Merck KGaA (Sigma-Aldrich)
- Siemens Healthineers AG
- Curium Pharma
Key Developments in Europe Nuclear Medicine Industry Industry
- June 2022: Curium submitted its Marketing Authorization Application for [18F]-DCFPyL for treating multiple stages of prostate cancer disease to the European Medicines Agency.
- May 2022: Turku PET Centre, Finland, introduced a new total-body Positron Emission Tomography (PET) scanner.
Future Outlook for Europe Nuclear Medicine Industry Market
The European nuclear medicine market is poised for continued growth, driven by technological innovations, the increasing prevalence of chronic diseases, and supportive regulatory environments. Strategic partnerships, focused R&D, and expansion into new therapeutic areas will shape the market’s future. The adoption of new imaging technologies and therapeutic approaches offers significant opportunities for growth and innovation in the years to come.
Europe Nuclear Medicine Industry Segmentation
-
1. Diagnostics
- 1.1. Single Photon Emission Computed Tomography (SPECT)
- 1.2. Positron Emission Tomography (PET)
-
2. Therapeutics
- 2.1. Alpha Emitters
- 2.2. Beta Emitters
- 2.3. Brachytherapy
-
3. Application
- 3.1. Cardiology
- 3.2. Neurology
- 3.3. Oncology
- 3.4. Other Applications
Europe Nuclear Medicine Industry Segmentation By Geography
- 1. Germany
- 2. United Kingdom
- 3. France
- 4. Italy
- 5. Spain
- 6. Rest of Europe
Europe Nuclear Medicine Industry Regional Market Share
Geographic Coverage of Europe Nuclear Medicine Industry
Europe Nuclear Medicine Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 10% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Incidence of Cancer and Cardiac Ailments; Increasing SPECT and PET Applications
- 3.3. Market Restrains
- 3.3.1. Strict Regulatory Guidelines
- 3.4. Market Trends
- 3.4.1. Oncology Segment is Expected to Register a Significant CAGR During the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Europe Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Diagnostics
- 5.1.1. Single Photon Emission Computed Tomography (SPECT)
- 5.1.2. Positron Emission Tomography (PET)
- 5.2. Market Analysis, Insights and Forecast - by Therapeutics
- 5.2.1. Alpha Emitters
- 5.2.2. Beta Emitters
- 5.2.3. Brachytherapy
- 5.3. Market Analysis, Insights and Forecast - by Application
- 5.3.1. Cardiology
- 5.3.2. Neurology
- 5.3.3. Oncology
- 5.3.4. Other Applications
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. Germany
- 5.4.2. United Kingdom
- 5.4.3. France
- 5.4.4. Italy
- 5.4.5. Spain
- 5.4.6. Rest of Europe
- 5.1. Market Analysis, Insights and Forecast - by Diagnostics
- 6. Germany Europe Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Diagnostics
- 6.1.1. Single Photon Emission Computed Tomography (SPECT)
- 6.1.2. Positron Emission Tomography (PET)
- 6.2. Market Analysis, Insights and Forecast - by Therapeutics
- 6.2.1. Alpha Emitters
- 6.2.2. Beta Emitters
- 6.2.3. Brachytherapy
- 6.3. Market Analysis, Insights and Forecast - by Application
- 6.3.1. Cardiology
- 6.3.2. Neurology
- 6.3.3. Oncology
- 6.3.4. Other Applications
- 6.1. Market Analysis, Insights and Forecast - by Diagnostics
- 7. United Kingdom Europe Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Diagnostics
- 7.1.1. Single Photon Emission Computed Tomography (SPECT)
- 7.1.2. Positron Emission Tomography (PET)
- 7.2. Market Analysis, Insights and Forecast - by Therapeutics
- 7.2.1. Alpha Emitters
- 7.2.2. Beta Emitters
- 7.2.3. Brachytherapy
- 7.3. Market Analysis, Insights and Forecast - by Application
- 7.3.1. Cardiology
- 7.3.2. Neurology
- 7.3.3. Oncology
- 7.3.4. Other Applications
- 7.1. Market Analysis, Insights and Forecast - by Diagnostics
- 8. France Europe Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Diagnostics
- 8.1.1. Single Photon Emission Computed Tomography (SPECT)
- 8.1.2. Positron Emission Tomography (PET)
- 8.2. Market Analysis, Insights and Forecast - by Therapeutics
- 8.2.1. Alpha Emitters
- 8.2.2. Beta Emitters
- 8.2.3. Brachytherapy
- 8.3. Market Analysis, Insights and Forecast - by Application
- 8.3.1. Cardiology
- 8.3.2. Neurology
- 8.3.3. Oncology
- 8.3.4. Other Applications
- 8.1. Market Analysis, Insights and Forecast - by Diagnostics
- 9. Italy Europe Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Diagnostics
- 9.1.1. Single Photon Emission Computed Tomography (SPECT)
- 9.1.2. Positron Emission Tomography (PET)
- 9.2. Market Analysis, Insights and Forecast - by Therapeutics
- 9.2.1. Alpha Emitters
- 9.2.2. Beta Emitters
- 9.2.3. Brachytherapy
- 9.3. Market Analysis, Insights and Forecast - by Application
- 9.3.1. Cardiology
- 9.3.2. Neurology
- 9.3.3. Oncology
- 9.3.4. Other Applications
- 9.1. Market Analysis, Insights and Forecast - by Diagnostics
- 10. Spain Europe Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Diagnostics
- 10.1.1. Single Photon Emission Computed Tomography (SPECT)
- 10.1.2. Positron Emission Tomography (PET)
- 10.2. Market Analysis, Insights and Forecast - by Therapeutics
- 10.2.1. Alpha Emitters
- 10.2.2. Beta Emitters
- 10.2.3. Brachytherapy
- 10.3. Market Analysis, Insights and Forecast - by Application
- 10.3.1. Cardiology
- 10.3.2. Neurology
- 10.3.3. Oncology
- 10.3.4. Other Applications
- 10.1. Market Analysis, Insights and Forecast - by Diagnostics
- 11. Rest of Europe Europe Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 11.1. Market Analysis, Insights and Forecast - by Diagnostics
- 11.1.1. Single Photon Emission Computed Tomography (SPECT)
- 11.1.2. Positron Emission Tomography (PET)
- 11.2. Market Analysis, Insights and Forecast - by Therapeutics
- 11.2.1. Alpha Emitters
- 11.2.2. Beta Emitters
- 11.2.3. Brachytherapy
- 11.3. Market Analysis, Insights and Forecast - by Application
- 11.3.1. Cardiology
- 11.3.2. Neurology
- 11.3.3. Oncology
- 11.3.4. Other Applications
- 11.1. Market Analysis, Insights and Forecast - by Diagnostics
- 12. Competitive Analysis
- 12.1. Market Share Analysis 2025
- 12.2. Company Profiles
- 12.2.1 Nordion Inc
- 12.2.1.1. Overview
- 12.2.1.2. Products
- 12.2.1.3. SWOT Analysis
- 12.2.1.4. Recent Developments
- 12.2.1.5. Financials (Based on Availability)
- 12.2.2 GE Healthcare
- 12.2.2.1. Overview
- 12.2.2.2. Products
- 12.2.2.3. SWOT Analysis
- 12.2.2.4. Recent Developments
- 12.2.2.5. Financials (Based on Availability)
- 12.2.3 Bracco Imaging SpA
- 12.2.3.1. Overview
- 12.2.3.2. Products
- 12.2.3.3. SWOT Analysis
- 12.2.3.4. Recent Developments
- 12.2.3.5. Financials (Based on Availability)
- 12.2.4 Advanced Accelerator Applications
- 12.2.4.1. Overview
- 12.2.4.2. Products
- 12.2.4.3. SWOT Analysis
- 12.2.4.4. Recent Developments
- 12.2.4.5. Financials (Based on Availability)
- 12.2.5 Cardinal Health Inc
- 12.2.5.1. Overview
- 12.2.5.2. Products
- 12.2.5.3. SWOT Analysis
- 12.2.5.4. Recent Developments
- 12.2.5.5. Financials (Based on Availability)
- 12.2.6 Merck KGaA (Sigma-Aldrich)
- 12.2.6.1. Overview
- 12.2.6.2. Products
- 12.2.6.3. SWOT Analysis
- 12.2.6.4. Recent Developments
- 12.2.6.5. Financials (Based on Availability)
- 12.2.7 Siemens Healthineers AG*List Not Exhaustive
- 12.2.7.1. Overview
- 12.2.7.2. Products
- 12.2.7.3. SWOT Analysis
- 12.2.7.4. Recent Developments
- 12.2.7.5. Financials (Based on Availability)
- 12.2.8 Curium Pharma
- 12.2.8.1. Overview
- 12.2.8.2. Products
- 12.2.8.3. SWOT Analysis
- 12.2.8.4. Recent Developments
- 12.2.8.5. Financials (Based on Availability)
- 12.2.1 Nordion Inc
List of Figures
- Figure 1: Europe Nuclear Medicine Industry Revenue Breakdown (undefined, %) by Product 2025 & 2033
- Figure 2: Europe Nuclear Medicine Industry Share (%) by Company 2025
List of Tables
- Table 1: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Diagnostics 2020 & 2033
- Table 2: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Therapeutics 2020 & 2033
- Table 3: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Application 2020 & 2033
- Table 4: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Region 2020 & 2033
- Table 5: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Diagnostics 2020 & 2033
- Table 6: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Therapeutics 2020 & 2033
- Table 7: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Application 2020 & 2033
- Table 8: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Country 2020 & 2033
- Table 9: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Diagnostics 2020 & 2033
- Table 10: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Therapeutics 2020 & 2033
- Table 11: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Application 2020 & 2033
- Table 12: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Country 2020 & 2033
- Table 13: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Diagnostics 2020 & 2033
- Table 14: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Therapeutics 2020 & 2033
- Table 15: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Application 2020 & 2033
- Table 16: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Country 2020 & 2033
- Table 17: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Diagnostics 2020 & 2033
- Table 18: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Therapeutics 2020 & 2033
- Table 19: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Application 2020 & 2033
- Table 20: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Country 2020 & 2033
- Table 21: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Diagnostics 2020 & 2033
- Table 22: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Therapeutics 2020 & 2033
- Table 23: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Application 2020 & 2033
- Table 24: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Country 2020 & 2033
- Table 25: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Diagnostics 2020 & 2033
- Table 26: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Therapeutics 2020 & 2033
- Table 27: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Application 2020 & 2033
- Table 28: Europe Nuclear Medicine Industry Revenue undefined Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Europe Nuclear Medicine Industry?
The projected CAGR is approximately 10%.
2. Which companies are prominent players in the Europe Nuclear Medicine Industry?
Key companies in the market include Nordion Inc, GE Healthcare, Bracco Imaging SpA, Advanced Accelerator Applications, Cardinal Health Inc, Merck KGaA (Sigma-Aldrich), Siemens Healthineers AG*List Not Exhaustive, Curium Pharma.
3. What are the main segments of the Europe Nuclear Medicine Industry?
The market segments include Diagnostics, Therapeutics, Application.
4. Can you provide details about the market size?
The market size is estimated to be USD XXX N/A as of 2022.
5. What are some drivers contributing to market growth?
Increasing Incidence of Cancer and Cardiac Ailments; Increasing SPECT and PET Applications.
6. What are the notable trends driving market growth?
Oncology Segment is Expected to Register a Significant CAGR During the Forecast Period.
7. Are there any restraints impacting market growth?
Strict Regulatory Guidelines.
8. Can you provide examples of recent developments in the market?
In June 2022, Curium submitted its Marketing Authorization Application for [18F]-DCFPyL for treating multiple stages of prostate cancer disease to the European Medicines Agency.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in N/A.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Europe Nuclear Medicine Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Europe Nuclear Medicine Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Europe Nuclear Medicine Industry?
To stay informed about further developments, trends, and reports in the Europe Nuclear Medicine Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence